Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

5(71.4%)

Phase 2

2(28.6%)

7Total

Phase 1(5)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT03098836Phase 2Completed

Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer

Role: lead

NCT02963051Phase 1Terminated

A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer

Role: lead

NCT04073160Phase 1Withdrawn

TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer

Role: lead

NCT01385228Phase 1Completed

Pazopanib, Docetaxel, Prednisone Prostate

Role: lead

NCT00303732Phase 1Completed

Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors

Role: lead

NCT00629525Phase 2Completed

RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer

Role: lead

NCT00788060Phase 1Completed

A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma

Role: lead

All 7 trials loaded